News
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch
Jaguar Health's Napo Pharmaceuticals to showcase Gelclair, an FDA-approved oral mucositis prescription product, at ASTRO Annual Meeting. Gelclair offers pain relief and support for cancer patients -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Appoints Industry Veteran to Head Sales for Company’s Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care
Jaguar Health, Inc. appoints Susan Krizancic as National Sales Director for Napo Pharmaceuticals, preparing for FDA-approved Gelclair® oral mucositis product launch in October 2024 -
-
